Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss

In this article

Regeneron Pharmaceuticals

will make its newly approved gene therapy for a rare, genetic form of hearing loss available for free in the U.S. The company hasn’t yet decided how much it will charge in other countries, Regeneron CEO Leonard Schleifer told CNBC on Friday.

“We haven’t set a price yet, but they should pay their fair share outside the United States,” Schleifer said in an interview with CNBC’s Becky Quick. “In the United States, we’re giving it away for free.“

Regeneron on Thursday announced it would make the therapy available for free in the U.S. alongside a larger deal with the Trump administration around drug pricing. President Donald Trump, for years, has argued that Americans are unfairly paying more for drugs than other wealthy nations and, as a result, is subsidizing innovation.